Tag: cabinet

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources

SAN FRANCISCO, 08 août 2025 (GLOBE NEWSWIRE) -- Rubicon Point Partners a annoncé la première clôture du Rubicon Point Fund II, un véhicule d’investissement immobilier ciblant des opportunités exceptionnelles sur la côte ouest des États-Unis, avec une concentration stratégique sur la baie de San Francisco. Lancé en janvier 2025, Fund II est indépendant du type de bien et offre la flexibilité nécessaire pour rester réactif et opportuniste sur un marché en constante évolution.

In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY, OR CONSTITUTE A VIOLATION OF, THE RELEVANT LAWS OF THAT JURISDICTION OR REQUIRE EURONEXT AND/OR ATHEX TO TAKE ANY FURTHER ACTION.

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx^® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.